Inhibition of Klebsiella pneumoniae carbapenemases by mycocins produced by Wickerhamomyces anomalus

New alternatives have been under study as treatment due to the problem of multidrug-resistant bacteria. Among them, Wickerhamomyces anomalus mycocins have shown a great potential against several microorganisms since they have high antimicrobial activity, as well as they can be used as fast available...

Full description

Saved in:
Bibliographic Details
Published in:Archives of microbiology Vol. 204; no. 12; p. 702
Main Authors: Nascimento, Bruna Larissa, Martelli, Eloiza Cristina, da Silva, Jessica Cassia, Delabeneta, Mateus Foltz, Rosseto, Lana Rubia Backes, Junges, Daniele Schaab Boff, Paris, Ana Paula, Persel, Cristiane, Paula, Claudete Rodrigues, Simão, Rita de Cássia Garcia, Gandra, Rinaldo Ferreira
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-12-2022
Springer Nature B.V
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:New alternatives have been under study as treatment due to the problem of multidrug-resistant bacteria. Among them, Wickerhamomyces anomalus mycocins have shown a great potential against several microorganisms since they have high antimicrobial activity, as well as they can be used as fast available nutrients and stand several extreme conditions. In this way, Klebsiella pneumoniae carbapenemases inhibition by mycocins produced by W. anomalus is important. Microdilution assays were carried out to evaluate strains inhibition in liquid medium and the test in solid medium were carried out. Toxicity was evaluated by both hemolysis and Artemia salina Leach tests. W. anomalus supernatant showed 2.36 U/mg β-glucanases activity, and antimicrobial activity was evidenced in 100% Klebsiella pneumoniae carbapenemase strains up to 0.12 U/mg concentration. Besides, there was low toxicity in hemolysis and Artemia salina Leach tests. It is suggested that W. anomalus mycocins may be an alternative to develop new antimicrobial substances.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0302-8933
1432-072X
DOI:10.1007/s00203-022-03311-z